The effect of breast cancer screening is declining

A new research result questions whether the benefits of breast cancer screenings has gradually declined to a degree that it is too small in relation to the costs in the form of overdiagnosis and overtreatment.

from Women's Health News -- ScienceDaily https://ift.tt/K6Jn5yx

The effect of breast cancer screening is declining

A new research result questions whether the benefits of breast cancer screenings has gradually declined to a degree that it is too small in relation to the costs in the form of overdiagnosis and overtreatment.

from Breast Cancer News -- ScienceDaily https://ift.tt/K6Jn5yx

The effect of breast cancer screening is declining

A new research result questions whether the benefits of breast cancer screenings has gradually declined to a degree that it is too small in relation to the costs in the form of overdiagnosis and overtreatment.

from Women's Health News -- ScienceDaily https://ift.tt/K6Jn5yx

'Structural racism' cited in study of breast-biopsy delays

Black and Asian women are more likely than white women to experience significant delays in getting breast biopsies after a mammogram identifies an abnormality. Moreover, those delays appear to be influenced by screening site-specific factors that may stem from structural racism, according to new research.

from Women's Health News -- ScienceDaily https://ift.tt/Jhk5vEo

Hormones contribute to sex disparities in bladder cancer, study shows

Male sex hormones interfere with the body's ability to fight bladder cancer, likely explaining why males experience higher cancer rates and more deadly disease, according to a new study.

from Women's Health News -- ScienceDaily https://ift.tt/mRCqSpJ

Hormones contribute to sex disparities in bladder cancer, study shows

Male sex hormones interfere with the body's ability to fight bladder cancer, likely explaining why males experience higher cancer rates and more deadly disease, according to a new study.

from Women's Health News -- ScienceDaily https://ift.tt/mRCqSpJ

Promising compound kills range of hard-to-treat cancers by targeting a previously undiscovered vulnerability

A compound called ERX-41 targets a previously unrecognized vulnerability in difficult-to-treat types of cancer including triple-negative breast cancer. The compound will be studied as a drug for clinical translation.

from Breast Cancer News -- ScienceDaily https://ift.tt/us3NwyM

Promising compound kills range of hard-to-treat cancers by targeting a previously undiscovered vulnerability

A compound called ERX-41 targets a previously unrecognized vulnerability in difficult-to-treat types of cancer including triple-negative breast cancer. The compound will be studied as a drug for clinical translation.

from Women's Health News -- ScienceDaily https://ift.tt/us3NwyM